STOCKHOLM, October 4 (Reuters) -Sweden Public Health Authority said on Monday that it recommended using Pfizer-BioNTechs (PFE.N), Comirnaty vaccine against COVID-19 for children between 12-15, choose against rival Moderna’s (MRNA.O ) Spikevax.
The European Medicines Agency approved the use of Comirnaty in May, while Spikevax received the nod for children over 12 in July. Read more
“Overall, we see reason to choose the vaccine we know the most about and which is most well-proven when it comes to vaccinating children between 12 and 15 years old,” says Anders Tegnell, head of department and state epidemiologist at the Swedish Health Authority.
The agency said there was more data on Comirnaty’s use of children.
“That is why Spikevax is not recommended for the youngest age group in Sweden,” the agency said in a statement.
In September, the agency said that children aged 12 and up would be offered a COVID vaccination from 11 October.
Reporting by Simon Johnson; Editing Toby Chopra
Our standards: Thomson Reuters Trust Principles.